Imatinib mesylate in children and adolescents with cancer Journal Articles

abstract

• AbstractImatinib is an inhibitor of the BCR–ABL fusion gene product that characterizes chronic myeloid leukemia (CML), and of the related tyrosine kinases c‐KIT and platelet‐derived growth factor (PDGF) receptor. The drug is now included as front‐line therapy for CML and Philadelphia chromosome‐positive acute lymphoblastic leukemia in children and adolescents, though valid concerns about serious late sequelae remain unresolved and are important issues for further study. European and North American consortia have conducted phase I and II clinical trials of imatinib in children and adolescents with brain and other solid tumors that have provided little evidence of efficacy. Pediatr Blood Cancer 2010;55:18–25. © 2010 Wiley‐Liss, Inc.

authors

• Barr, Ronald Duncan

status

• published 

publication date

• July 15, 2010

has subject area

• 1103 Clinical Sciences (FoR)
• 1112 Oncology and Carcinogenesis (FoR)
• 1114 Paediatrics and Reproductive Medicine (FoR)
• Adolescent (MeSH)
• Benzamides (MeSH)
• Child (MeSH)
• Humans (MeSH)
• Imatinib Mesylate (MeSH)
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (MeSH)
• Oncology & Carcinogenesis (Science Metrix)
• Philadelphia Chromosome (MeSH)
• Piperazines (MeSH)
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (MeSH)
• Pyrimidines (MeSH)

published in

• Pediatric Blood and Cancer  Journal

keywords

• Adolescent
• Benzamides
• Child
• Humans
• Imatinib Mesylate
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Philadelphia Chromosome
• Piperazines
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Pyrimidines

Digital Object Identifier (DOI)

• 10.1002/pbc.22484

PubMed ID

• 20486169

start page

• 18

end page

• 25

volume

• 55

issue

• 1